Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-08-03 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于第五届董事会第十二次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of resolutions passed at the 12th meeting of the 5th Board of Directors of 特一药业集团股份有限公司 on August 3, 2023. It details approvals related to a simplified procedure for a private placement of shares to specific investors, including subscription agreements, issuance plans, feasibility reports, and authorization to open special accounts for raised funds. The document includes voting results and references to regulatory compliance with Chinese securities laws and Shenzhen Stock Exchange rules. It does not contain financial statements or detailed financial performance data but rather reports on board decisions regarding capital raising activities. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2023-08-03 Chinese
关于2023年度以简易程序向特定对象发行股票摊薄即期回报及填补措施和相关主体承诺（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding a 2023 stock issuance to specific investors using a simplified procedure. It discusses the dilution impact on immediate returns, financial assumptions, risk warnings, and measures to mitigate dilution effects. It includes financial projections, governance and management commitments, and regulatory references to Chinese securities laws and guidelines. The content focuses on capital raising, its impact on financial metrics, and related commitments rather than presenting a full financial report or earnings release. The document is not a full annual or interim report, nor is it a simple announcement of a report. It is a capital/financing update about a specific stock issuance and related dilution and mitigation measures. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-03 Chinese
关于公司完成注册资本工商变更登记及章程备案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the completion of registration capital change and amendment of the company charter, including details of board and shareholder meetings approving these changes. It does not contain financial statements or detailed financial data but rather informs about corporate governance and capital structure updates. The document length is short (1240 characters) and it is a formal announcement of completed corporate actions rather than a full report. This fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about corporate changes that does not fit into more specific categories like capital change announcement (SHA) because it focuses on the completion and registration of changes rather than the initial announcement of share issuance or capital change.
2023-08-02 Chinese
关于变更募集资金持续督导保荐代表人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representatives related to the company's fundraising activities. It mentions the appointment and replacement of individuals responsible for overseeing the use of raised funds and the sponsorship of a specific stock issuance. There is no financial data, report, or detailed financial analysis presented. The document is a regulatory announcement about changes in the supervision of fundraising activities, not a full report or financial statement. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on sponsorship and fundraising supervision changes, which aligns with CAP rather than other categories like Annual Report or Regulatory Filings.
2023-07-21 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of 特一药业集团股份有限公司. It includes information about the meeting date, voting methods, attendance, voting results on multiple proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes at a general meeting, including detailed vote counts and percentages. There is no indication that this is a full annual report, earnings release, or other financial report. The document is not a proxy solicitation or a management report but specifically reports the voting results of the shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters but contains substantive voting results, not just an announcement of a report publication, so it is not RPA or RNS. Confidence is high due to the clear presence of voting results and meeting details.
2023-07-13 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2023年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening, attendance, and voting procedures of a company's 2023 first extraordinary general meeting (临时股东大会). It details the meeting's notice, attendance, voting results, and confirms compliance with relevant laws and company articles. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a legal opinion related to a shareholder meeting, specifically focusing on the voting process and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting. The document length is under 5,000 characters, but it contains detailed voting results and legal opinion, not just an announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2023-07-13 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.